Toronto · Independent Shariah screening · Updated daily
Market news · Researched from public market reporting · Content-only (no affiliate programs)

Eli Lilly Surged on GLP-1 Earnings: the Halal Investor's Read (2026)

Eli Lilly delivered the earnings season's clearest demand story on the morning of Thursday 29 October 2026: third-quarter revenue of $24.4 billion, up 39% from a year earlier, driven by diabetes and obesity drugs that are now selling at a scale few pharmaceutical franchises have ever reached. Mounjaro alone generated $10.72 billion in the quarter, up 65%, and Zepbound added $5.35 billion, up 49%. The company raised its full-year revenue guidance by $5.5 billion at the midpoint, to $91 billion to $92 billion, and its shares rose about 3% to 4% in premarket trading. The print was not flawless — the adjusted profit forecast came down, a new obesity pill missed expectations, and prices fell even as volumes soared — and that mixture is exactly what makes it worth reading carefully. This article reports what Lilly actually printed, why the market cheered a quarter that also lowered the profit outlook, what the same morning's very different earnings reactions say about expectations, and how a halal investor should read a surge like this: through the screen first, the price second.

Updated October 2026 · Reviewed by the Canadian Halal Investor team

What happened this morning

Lilly reported before the opening bell on Thursday 29 October 2026, into a market still digesting the previous night's split verdict from Alphabet and Microsoft, which this site covered in this morning's article. The contrast between the two sessions is instructive. Last night's story was about spending: whether enormous artificial intelligence investment is turning into cash. This morning's story is about demand: whether the world's most successful drug franchise can keep growing fast enough to justify the expectations built into its price. On the headline numbers, it can. Revenue of $24.4 billion beat the Zacks consensus estimate of $22.11 billion by 10.4%, and adjusted earnings per share of $7.48 beat the Zacks consensus of $5.38 by 39%. Reported net income rose 16% to $6.45 billion, and reported earnings per share rose 16% to $7.22.

The premarket reaction was positive but measured: shares rose about 3% to 4%, with Dow Jones reporting a 3.3% rise to $1,331 in premarket trading. That restraint, after a beat of this size, is itself a piece of information. Lilly is one of the most richly valued large companies in the market, and a beat has to clear a high bar simply to hold the price, let alone lift it sharply. The market's verdict, in other words, was not "good quarter" or "bad quarter" but "good quarter, mostly expected, with two blemishes worth noting." The rest of this article works through each part of that verdict, because a halal investor's job on an earnings day is not to celebrate or mourn a price move but to check what changed about the business, the balance sheet, and the screen.

The numbers behind the surge

Start with the engine. Mounjaro, Lilly's diabetes drug, generated $10.72 billion in quarterly revenue, up 65% from a year earlier. Zepbound, the obesity drug built on the same active ingredient, generated $5.35 billion, up 49%. Together the two drugs account for roughly two-thirds of Lilly's quarterly revenue, which is both the strength of the quarter and its concentration risk: the investment case for Lilly is, to a large extent, the investment case for one molecule family. Newer products also contributed to growth, and the quarter included approximately $900 million of benefits from $410 million in Jardiance milestones — the company noted no further such milestones remain — plus favourable adjustments to rebate and discount estimates. Stripping those one-time benefits out still leaves a quarter of exceptional underlying growth, but a careful reader should note them, because they flatter the year-over-year comparison and will not repeat.

The volume-versus-price split is the quarter's most interesting detail. Total volumes rose 53%, while net realised prices declined 15%. In plain terms, Lilly sold far more medicine at lower net prices per unit — the pattern of a company expanding access and absorbing pricing pressure at the same time, rather than raising prices on a fixed customer base. United States revenue rose 34% to $15.1 billion, while revenue outside the United States rose 47% to $9.3 billion, so the growth is global rather than a single-market story. For a screened investor, this split matters more than the headline growth rate: volume-led growth is generally more durable than price-led growth, because it rests on more patients and more prescriptions rather than on pricing power that regulators and payers can challenge. It is also, however, more capital-intensive, since serving more patients requires more manufacturing capacity — and Lilly's dealmaking this quarter shows where some of that capital is going.

The quarter also carried regulatory and pipeline news that extends beyond the income statement. The US Food and Drug Administration approved Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes, approved Onswik, a once-weekly basal insulin, approved Inluriyo in combination with Verzenio for certain advanced breast cancers, and expanded the indication for Jaypirca in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma. On the pipeline, Lilly reported positive topline results from a head-to-head Phase 3 trial of retatrutide against Ozempic 2 mg in adults with type 2 diabetes, Phase 3 results for Ebglyss in moderate-to-severe hand and foot atopic dermatitis, and Phase 2 results for EloraTZP in obesity and type 2 diabetes, with Phase 3 trials to start in the fourth quarter of 2026. None of these items changes a screen result, but together they describe a company whose growth story is being refreshed from several directions at once, not resting on a single drug.

Why the market cheered a lower profit forecast

The apparent contradiction in the quarter — revenue guidance up, profit guidance down, shares up — resolves once the charges behind the profit cut are understood. Lilly raised its 2026 revenue guidance to $91 billion to $92 billion, up from $85 billion to $87 billion, an increase of $5.5 billion at the midpoint. It also updated adjusted earnings per share guidance to $35 to $36, down from $35.50 to $36.50 previously. The company explained the move precisely: it raised its underlying non-GAAP earnings guidance by $4.07 per share at the midpoint, but that increase was more than offset by $4.57 per share in acquired in-process research and development charges from third-quarter business development, principally the completed acquisitions of AtaiBeckley and Curevo. In other words, the operating business is performing better than previously expected, and the reported profit forecast fell because the company spent heavily on acquiring future pipeline assets, not because its existing drugs faltered.

Markets generally treat acquisition-related research charges differently from operating weakness, which is why shares rose despite the lower profit range. But a halal investor should not wave the charges through unexamined, for two reasons. First, dealmaking is a choice about where capital goes: $4.2 billion in acquired research charges in a single quarter, plus a newly announced agreement to buy Merida Biosciences to develop treatments for serious autoimmune and allergic diseases, describes a company converting today's drug profits into tomorrow's pipeline at a rapid pace. That strategy only pays if the acquired assets eventually produce approved medicines. Second, acquisitions are where balance sheets change: a debt-funded buying spree would eventually show up in the debt ratio that the Shariah screen measures, which is why the screen section below checks the ratio rather than assuming it. Lilly's current headroom is large, as that section shows, but headroom is a snapshot, not a guarantee.

The quarter's genuine blemish deserves equal attention. Sales of Foundayo, Lilly's new GLP-1 obesity pill launched in the United States in April, came in below Wall Street's expectations for the quarter, according to market reporting. A pill version of a GLP-1 drug matters commercially because injections deter some patients, so a soft launch tempers one of the growth stories investors had priced in. It does not change the quarter's overall verdict — two blockbuster injectables growing 65% and 49% outweigh one soft pill launch — but it is a reminder that even dominant franchises have execution risk in new formats, and that expectations, not just results, set prices. Shares rose only modestly on a large beat partly because parts of the print, including Foundayo and the lowered profit range, gave the market reasons to hold back.

The same morning elsewhere: beats that fell

Thursday morning also delivered the earnings season's standing lesson in expectations, and it is worth pausing on because it directly protects a screened investor from the most common earnings-day mistake: assuming a good report means a rising price. Fortinet, the cybersecurity company, was the largest S&P 500 decliner in premarket trading, down about 27%, despite beating third-quarter expectations and raising its outlook — after a gain of roughly 119% earlier in the year, the market wanted evidence of growth in artificial-intelligence data-centre firewall deals first, and the print did not satisfy that specific demand. ServiceNow fell about 19% after reporting earnings per share of $0.27 against $0.35 expected, even though it raised its full-year subscription revenue outlook and its remaining performance obligations rose 20.5% to $13.65 billion. Caterpillar fell about 10% after beating on earnings per share — $7.20 against $7.08 expected — while holding its sales growth outlook unchanged, with revenue up 17% to $20.7 billion.

The pattern across all three is the same: the market does not grade reports against zero, it grades them against what was already priced in, and against the specific question each company's investors were asking. A beat on the wrong question, or a guide that merely confirms rather than raises, can produce a double-digit fall on an objectively strong quarter. That is why this site's earnings coverage keeps returning to the same discipline: read the print, check the screen, and ignore the size of the move as a signal about quality. Lilly rose on its beat and Fortinet fell on its beat, and neither move, by itself, tells you anything about whether either business passes a Shariah screen. The screen measures the business and the balance sheet; the market measures the gap between reality and expectation. Both are useful, and they answer different questions.

The rest of the day keeps the earnings calendar busy. Amazon and Intel report after the close today, alongside Starbucks, Coinbase and Rivian, according to the day's earnings calendar, while Mastercard and Merck reported before the open. Each will produce a mover that deserves the same treatment as this morning's: separate fact from expectation, check the screen before the price, and decide on the business rather than the move. For the running list of every trending story, see the market news page.

What the Shariah screen says about Eli Lilly

Here is the question this article exists to answer: does a 39% revenue surge, a raised revenue forecast, and a $4.2 billion acquisition charge change whether Eli Lilly is halal to hold? On this site's October 2026 screening, the answer is no — and the reasons are worth stating precisely, because they show what the screen measures and what it does not.

The screen has two gates, applied in order, as documented on our methodology page. Gate one is business activity: is the company's core business permissible? Lilly's business — prescription pharmaceuticals spanning diabetes, obesity, oncology, immunology and neuroscience — passes, and our Eli Lilly screener sets out the full result. Nothing in this quarter's report changes the business: the company sold more of the same categories of medicine, won approvals in the same categories, and acquired pipeline assets in adjacent therapeutic areas. A quarter in which a pharmaceutical company grows by selling medicine is, from a gate-one perspective, an uneventful quarter, however dramatic the growth rate.

Gate two applies financial ratios, and here the October 2026 figures leave Lilly far from its ceilings. Interest-bearing debt is 5.0% of market capitalisation ($54.91 billion of debt on roughly $1,093.6 billion of market capitalisation), cash and short-term investments are 0.8%, and non-compliant income is effectively zero — Lilly reports net interest expense rather than interest income, paying $527 million in net interest in the first half of 2026 rather than earning it. The ceilings providers use are roughly 30% to about 33% for debt and cash — providers differ, with this site's AAOIFI-style figure at 30% and others near 33%, a disagreement this site reports rather than resolves — and 5% for non-compliant income. Against either debt ceiling, a 5.0% ratio passes by a wide margin, and the acquisition charges this quarter were research expenses, not new borrowing, so they do not push the debt ratio toward the ceiling by themselves. What deserves a re-check at the next screening update is the direction of the ratio if dealmaking continues at this pace and is funded with debt rather than from the company's own cash generation.

Shariah callout: a surge is not a screen result. Lilly's revenue jumped 39% and its shares rose, Fortinet beat expectations and its shares fell about 27%, and neither move changed either company's business activity or pushed any ratio near its ceiling. The screen answers whether a business is investable for a halal investor; the market answers what happened to its price today. Confusing the two — buying a company because it surged, or selling a passing company because it fell — is the most common earnings-day error. Nothing here is a fatwa: published standards and screener data are reported as facts, and rulings on your situation belong with a qualified scholar. See our Ask a Scholar page. Not financial advice. Facts and screening methodology only — no fatwas.

The contrast with this week's earlier stories sharpens the point. Celestica surged 11.9% on AI earnings on Tuesday, yet fails this site's screen at gate one because of its Aerospace and Defense business, whatever its ratios say. Alphabet fell about 10% while Microsoft rose on Wednesday night, yet both still pass the screen, because a price move is not a compliance event. Lilly is the third pattern: a company that passes, surging on genuine demand, with the interesting questions sitting not in compliance but in concentration — two drugs driving roughly two-thirds of revenue — and in funding — whether an accelerating acquisition pace stays inside the balance-sheet headroom the screen measures. A halal investor who holds Lilly, or is considering it, should therefore ask a different question from the market's: not "how fast is it growing," but "does the screen still pass, and is the funding mix moving toward or away from the ceilings?" On October's figures, the answer to the first question is yes, and the second question is one to revisit when the next screening update lands.

For Canadian holders, two practical notes complete the picture. First, Lilly reports in US dollars and trades in US dollars, so a Canadian investor's return in Canadian dollars also reflects the exchange rate — a currency effect, not a compliance effect, and one that cuts both ways over time. Second, registered accounts do not change any of this: a TFSA or RRSP changes the tax treatment of what sits inside it, not the compliance of the holding, as our halal RRSP guide explains. And for investors who receive dividends, our purification guide covers the small impure portion that screened dividends can still carry — though in Lilly's case, because the company is a net payer of interest rather than an earner, there is effectively nothing to purify, and our purification calculator can confirm the arithmetic on any holding.

An earnings-day checklist for a halal investor

Earnings season produces more commentary than almost any other market event, and most of it is noise for a screened investor. A short checklist, run in order, filters it. None of these steps is a buy or sell call; together they are a decision procedure for any earnings day, including this one.

  1. Separate the print from the price. Lilly's revenue, drug sales, guidance and charges are facts; the 3% to 4% premarket rise is the market's reaction to them. Fortinet's 27% fall on a beat proves the reaction is not a quality rating. Read the print first, the price second.
  2. Check the screen before the chart. Run the ticker through the screener hub or one of the apps in the screener roundup before drawing any conclusion from a price move. A surging price is not a passed screen, and a falling price is not a failed one.
  3. Ask what drove the growth. Volume-led growth, like Lilly's 53% volume increase, rests on more patients and prescriptions; price-led growth rests on pricing power that payers and regulators can challenge. The driver matters more than the growth rate.
  4. Ask how the growth is funded. Acquisition charges and deal announcements are claims on future cash. A company funding growth from operations is a different balance-sheet story from one funding it with debt, and the debt gate is where that story eventually shows up.
  5. Watch concentration, not just growth. When two drugs drive roughly two-thirds of revenue, the key risk is not this quarter's growth rate but what happens if one franchise slows. Concentration is a business question the screen does not measure, which is why it belongs on your own checklist.
  6. Write down what you will watch, then stop watching. For Lilly, that is the next quarter's Mounjaro and Zepbound sales, the Foundayo launch trajectory, the next screening update's debt ratio, and chief rival Novo Nordisk's third-quarter results, due 4 November. Note those markers, note what would actually change your plan — a screen result changing — and ignore the hourly commentary in between.

That last step is the one most investors skip, and it is the one earnings days most reward. A portfolio reviewed on a short list of markers, and otherwise left alone, will beat a portfolio reviewed on every premarket tick. The screen does the compliance work; the calendar does the patience work.

What to watch next

The rest of this week gives the framework several live tests. Amazon and Intel report after the close today, 29 October, alongside Starbucks, Coinbase and Rivian, and each will produce a mover that deserves the same treatment as this morning's: separate fact from expectation, check the screen before the price, and decide on the business rather than the move. On 4 November, Novo Nordisk reports its third quarter, giving the first like-for-like comparison with Lilly's print and a read on whether GLP-1 demand is lifting the whole class or consolidating around one leader. The Federal Reserve's December meeting on 8 to 9 December is the next macro marker, with markets pricing a high chance of a further increase after the 28 October hold; none of that intraday noise changes a screen result by itself.

For the running list of every trending story, see the market news page, and for yesterday's split mega-cap verdict through the same lens, see Alphabet fell 10% as Microsoft beat: the AI spending test through a halal lens. Earnings season will come again next quarter, and the checklist above will still apply, unchanged, because the screen it serves does not move with any single print — it moves only when a business or its ratios do.

FAQ

What did Eli Lilly report for the third quarter of 2026?

Eli Lilly reported revenue of $24.4 billion, up 39 percent from a year earlier, against a Zacks consensus estimate of $22.11 billion, and adjusted earnings per share of $7.48 against a Zacks consensus of $5.38. Mounjaro sales rose 65 percent to $10.72 billion, Zepbound sales rose 49 percent to $5.35 billion, and reported net income rose 16 percent to $6.45 billion.

Why did Lilly raise its revenue forecast but cut its profit forecast?

Lilly raised 2026 revenue guidance to $91 billion to $92 billion, up from $85 billion to $87 billion, because the operating business is performing better than previously expected. It trimmed adjusted earnings per share guidance to $35 to $36, from $35.50 to $36.50, because $4.57 per share in acquired research charges from third-quarter deals more than offset a $4.07 per share rise in underlying profit guidance.

What are Mounjaro and Zepbound, and why do they matter to the quarter?

Mounjaro is Lilly's diabetes drug and Zepbound is its obesity drug, built on the same active ingredient. Together they generated about $16.07 billion in the quarter, roughly two-thirds of Lilly's revenue, so their growth of 65 percent and 49 percent respectively is the main reason revenue rose 39 percent, and also the main concentration risk in the investment case.

Does Eli Lilly pass this site's Shariah screen?

Yes, as of October 2026. Lilly's prescription pharmaceutical business passes the business-activity gate, interest-bearing debt is 5.0 percent of market capitalisation, cash is 0.8 percent, and non-compliant income is effectively zero because the company reports net interest expense rather than interest income. This is a screening result, not a religious ruling.

Does a big earnings beat change whether a stock is halal to hold?

No. A price move does not change a company's business activity, and as of October 2026 Lilly passes this site's screen with debt at 5.0 percent of market capitalisation against ceilings of 30 percent to about 33 percent, depending on the provider. Fortinet fell about 27 percent on the same morning despite beating expectations, which shows a price move is not a compliance verdict in either direction.

Is anything in this article a fatwa or a buy or sell call?

No. Everything here is facts and screening methodology only, with no fatwas and no personalised buy or sell calls. Rulings on your own situation belong with a qualified scholar, and investment decisions belong with advice suited to your circumstances.

Affiliate disclosure. This page contains no affiliate links, and the site currently earns no affiliate revenue. If we join affiliate programs in the future, this disclosure will be updated and links will be clearly labeled. Commissions never influence our scores or rankings — this review is based on official documentation and public data, and every product is Shariah-screened before review. Nothing on this site is financial advice.